In vitro activity of sulbactam-durlobactam against colistin-resistant and/or cefiderocol-non-susceptible, carbapenem-resistant Acinetobacter baumannii collected in U.S. hospitals.
Antimicrob Agents Chemother
; 68(3): e0125823, 2024 Mar 06.
Article
in En
| MEDLINE
| ID: mdl-38289078
ABSTRACT
The activity of a novel ß-lactamase inhibitor combination, sulbactam-durlobactam (SUL-DUR), was tested against 87 colistin-resistant and/or cefiderocol-non-susceptible carbapenem-resistant Acinetobacter baumannii clinical isolates collected from U.S. hospitals between 2017 and 2019. Among them, 89% and 97% were susceptible to SUL-DUR and imipenem plus SUL-DUR, with MIC50/MIC90 values of 2 µg/mL/8 µg/mL and 1 µg/mL/4 µg/mL, respectively. The presence of amino acid substitutions in penicillin-binding protein 3, including previously reported A515V or T526S, was associated with SUL-DUR non-susceptibility.
Key words
Full text:
1
Database:
MEDLINE
Main subject:
Acinetobacter Infections
/
Acinetobacter baumannii
/
Azabicyclo Compounds
Limits:
Humans
Language:
En
Journal:
Antimicrob Agents Chemother
Year:
2024
Type:
Article
Affiliation country:
United States